Bio Pharma Dive
JULY 11, 2022
Flagship Pioneering’s latest startup aims to use predictive technology to find “variant-proof” treatments and vaccines for infectious diseases before they might be needed.
Pharmaceutical Technology
JULY 12, 2022
Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 15, 2022
To address the “retention” problem, pharma companies are paying employees exorbitant salaries. The problem with that system is that people do whatever they need to to “hold onto” their high-paying jobs and become employees who are content not to excel. This is NOT what pharma needs. Last week I briefly chatted with someone in the industry evaluating another job offer.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 12, 2022
The World Health Organization said Wednesday it will reconvene its monkeypox experts to decide if the worsening outbreak now constitutes a global public health emergency – the highest level of alert. The UN health agency’s director-general Tedros Adhanom Ghebreyesus said he would hold a second meeting of the emergency committee on monkeypox, with more than […].
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JULY 11, 2022
Phase three oncology studies have approximately a 35% likelihood of leading to regulatory approval.
Pharmaceutical Technology
JULY 15, 2022
Despite entering its fourth decade of availability, in vitro fertilization (IVF), a medical technique used to facilitate the conception of a baby for those facing fertility problems, remains an elusive dream for many. Artificial intelligence (AI) could change this, with many researchers looking to harness the technology to increase IVF’s reliability, affordability, and availability.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 14, 2022
The COVID-19 pandemic has seen multiple lockdowns in multiple countries as governments have tried to limit transmission – and a new study uses those lockdowns to look at how we experience isolation and feelings of loneliness. What’s clear is that we all experience being on our own differently. For some people, it can be damaging […].
Bio Pharma Dive
JULY 14, 2022
A shaky biotech market has forced another drugmaker to adjust, with CytomX revealing plans to reduce its workforce by 40%.
Pharmaceutical Technology
JULY 15, 2022
Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada. The two-dose initial vaccine regimen in children of this age group is completed in one month, which is the same dosing schedule in adults, adolescents and children aged above
NPR Health - Shots
JULY 15, 2022
Mental health advocates hope the new hotline will make it much easier to get support if you're in crisis or helping someone who is. Here's how it works and what could stand in its way.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 10, 2022
A new anti-hangover supplement has just gone on sale in the UK. It is marketed by Swedish firm Myrkl as “the pre-drinking pill that works” The pill is said to break down up to 70 percent of alcohol after 60 minutes. This means that if someone drinks 50 ml of 40 percent spirits, which contains […].
Bio Pharma Dive
JULY 12, 2022
A former Celgene executive, Jackie Fouse has led Agios since 2019, overseeing its transformation into a company focused solely on uncommon diseases. In August, she will transition to chair its board of directors.
Pharmaceutical Technology
JULY 13, 2022
Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Under the deal, the companies will also develop various other drugs that act on cytochrome P450 11A1 (CYP11A1), an enzyme vital for steroid production.
NPR Health - Shots
JULY 13, 2022
Global health meetings are often held in the West — and that's an obstacle for scientists, doctors and advocates from lower resource countries. Which means their voices aren't being heard.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 11, 2022
The link between air pollution and autoimmune diseases just got a little clearer thanks to a massive study that dove into the health records of over 6 million Canadians. Led by public health researcher Naizhuo Zhao of McGill University, the study found that long-term exposure to air pollutants was associated with a slightly increased […].
Bio Pharma Dive
JULY 11, 2022
For $320 million, Vertex said it plans to buy ViaCyte in a deal that would provide “complementary assets, capabilities and technologies” to the ones it picked up through the 2019 acquisition of Semma Therapeutics.
Pharmaceutical Technology
JULY 11, 2022
Research and innovation in supply chain & logistics in the pharmaceutical sector has declined in the last year. The most recent figures show that the number of supply chain and logistics related patent applications in the industry stood at 17 in the three months ending May - down from 21 over the same period in 2021. Figures for patent grants related to supply chain and logistics followed a similar pattern to filings - shrinking from 2 in the three months ending May 2021 to 1 in the same per
NPR Health - Shots
JULY 13, 2022
Pfizer and Moderna have refused to divulge details of how to make their cutting-edge COVID shots. Here's what two scientists — and longtime best friends — are doing about it.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 13, 2022
The search for a way to treat Alzheimer’s disease has puzzled scientists for decades. This may be why some researchers are shifting their focus slightly, investigating whether treating the systems affected by Alzheimer’s (as opposed to the causes) may better help them find a treatment. This is exactly what researchers of a new study have […].
Bio Pharma Dive
JULY 15, 2022
The regulator said there have been “a few” spontaneous severe allergic reactions following administration of the vaccine, which was this week authorized in the U.S.
Pharmaceutical Technology
JULY 15, 2022
The Brazilian Health Regulatory Agency (Anvisa) has granted emergency use authorization for Sinovac Biotech’s Covid-19 vaccine, CoronaVac, in children aged three to five years. Subjects in this age group can receive the same vaccine dosage authorised in patients aged six to 17 years, as well as adults. Furthermore, there exists no restriction on vaccine usage in immunosuppressed children aged three to five years.
NPR Health - Shots
JULY 14, 2022
A federal judge ordered thousands of dogs to be rehomed from a Virginia research facility after several inspections revealed poor conditions. Animal rescue groups are working to do just that.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 13, 2022
A sophisticated second pharma park with all the modern infrastructure facilities will be set up at Tindivanam in Tamil Nadu with the active support of the state government, for which the MSME department is actively coordinating with the ministries of Industry and Finance, according to V Arun Roy, secretary to MSME department. The secretary wanted […].
Bio Pharma Dive
JULY 15, 2022
The Danish drugmaker will buy a priority review voucher from Marinus Pharmaceuticals, the latest in a string of similarly priced purchases.
Pharmaceutical Technology
JULY 12, 2022
Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. The Roflumilast cream is a once-a-day topical formulation of the selective phosphodiesterase type 4 (PDE4) inhibitor, roflumilast. A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses.
BioPharma Reporter
JULY 13, 2022
Moderna has dosed the first participant in a Phase 1 trial of its Nipah virus vaccine candidate, mRNA-1215, that has been developed in collaboration with the US National Institutes of Health (NIH).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 11, 2022
The Indian Institute of Management, Bangalore (IIM-B) has now driven its agenda to create the right healthcare leadership workforce with its year-long programme on hospital management. The Institute has devised the curriculum that is directed to benefit healthcare professionals to mould them into management cadre candidates. It would benefit mid-level managers, healthcare consultants, entrepreneurs and […].
Bio Pharma Dive
JULY 14, 2022
The deferral puts the drug in regulatory limbo, setting back the Swiss pharma's efforts to catch up to top immunotherapy developers Merck, Bristol Myers Squibb and Roche.
Pharmaceutical Technology
JULY 12, 2022
Novavax has signed an agreement with the US Department of Health and Human Services (HHS), in partnership with the Department of Defense, under which the US government will procure 3.2 million doses of the company’s Covid-19 vaccine, NVX-CoV2373, in the initial stage. The order is contingent on the vaccine obtaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) as well as the Centers for Disease Control and Prevention (CDC) recommendation.
NPR Health - Shots
JULY 14, 2022
With COVID safety protocols rescinding around the country, many are returning to a sense of pre-pandemic normalcy. But disabled and immunocompromised people can't do so, and are being left behind.
Expert insights. Personalized for you.
357 
Let's personalize your content